Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines!Free Sample is available!
Here come GMP Grade Cytokines!Free Sample is available!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
GPRC5D VHH - 01 | PCC | Hematological Malignancy | Multiple myeloma |
FACS Analysis of CHO/Human GPRC5D Stable Cell Line.
FACS assay shows that Anti-GPRC5D antibody can bind to CHO/Human GPRC5D Stable Cell Line (Fig. B), and non-transfected CHO cells were used as a negative control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).
Anti-GPRC5D Antibody, Human IgG4 captured on Protein A Chip can bind Human GPRC5D Full Length Protein, Flag,His Tag (Cat. No. GPD-H52D5) with an affinity constant of 57.7 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Talquetamab | JNJ-7564; JNJ-64407564 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TALVEY | United States | Multiple Myeloma | Janssen Biotech Inc | 2023-08-09 | Hematologic Neoplasms; Multiple Myeloma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Arlocabtagene autoleucel | CC-95266; BMS986393; BMS-986393 | Phase 3 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
LM-305 | LM-305 | Phase 2 Clinical | LaNova Medicines Ltd | Multiple Myeloma | Details |
BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital) | Phase 2 Clinical | Peking University People'S Hospital | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myositis; Immunoglobulin G4-Related Disease; Sjogren's Syndrome; Scleroderma, Systemic; Antiphospholipid Syndrome; Lupus Erythematosus, Systemic; Acquired thrombotic thrombocytopenic purpura; Behcet Syndrome | Details | |
BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Multiple Myeloma | Details | |
CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of Health | Plasmacytoma; Multiple Myeloma | Details | |
Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene) | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Multiple Myeloma | Details | |
MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
CT-071 | CT071; CT-071 | Phase 2 Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
Anti-GPRC5D CAR-T Cells Therapy(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details | |
Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
Ori-CAR-017 | Ori-CAR-017; OriCAR-017; GPRC5D-CAR-T | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Hemorrhagic Disorders; Hematologic Diseases; Hemostatic Disorders; Paraproteinemias; Immunoproliferative Disorders; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Immune System Diseases; Vascular Diseases; Neoplasms, Plasma Cell; Cardiovascular Diseases; Lymphoproliferative Disorders | Details |
LBL-034 | LBL-034 | Phase 2 Clinical | Nanjing WeiLibo biological Technology Co Ltd | Neoplasms; Multiple Myeloma | Details |
SAR-446523 | SAR-446523 | Phase 1 Clinical | Sanofi-Aventis Gmbh | Bone Marrow Neoplasms; Multiple Myeloma | Details |
CM-380 | CM380; CM-380 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
OL-101 | OL-101 | Phase 1 Clinical | Overland Pharmaceuticals (Shanghai) Co Ltd | Multiple Myeloma | Details |
RD-140 | RD140 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) | Phase 1 Clinical | The Second People Hospital Of Guangdong Province | Multiple Myeloma | Details | |
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) | BMS-986453 | Phase 1 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
SIM-0500 | SIM0500; SIM-0500 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
QLS-32015 | QLS-32015; QLS32015 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Multiple Myeloma | Details |
Anti-GPRC5D CAR-T Cells Therapy (Guangzhou Bio-Gene Technology Co Ltd) | Phase 1 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Multiple Myeloma | Details | |
OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | Zhejiang University, OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
CAR-GPRC5D | CAR-GPRC5D; RD-118; RD118 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
Forimtamig | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
MCARH-109 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc | Multiple Myeloma | Details | |
RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics) | ACT-001(Acellytron Therapeutics) | Clinical | Acellytron Therapeutics | Multiple Myeloma | Details |
This web search service is supported by Google Inc.